Abstract 484: Pre-treatment platelet counts as a prognostic factor in stage II and III rectal adenocarcinoma

Ioannis Voutsadakis; Morgan Steele

doi:10.1158/1538-7445.AM2016-484

Background. Thrombocytosis is often associated with malignancies and has been confirmed as an adverse prognostic factor in various cancers. We investigated if pre-treatment elevated platelet counts could provide prognostic information in patients with stage II and III rectal adenocarcinoma that received neo-adjuvant treatment before surgery. Patients and Methods. Platelet number on diagnosis of stage II and III rectal cancer was evaluated in 51 patients receiving neo-adjuvant treatment and for whom there were complete follow-up data on progression and survival, as well as pathologic outcome at time of surgery. Pathologic response after neo-adjuvant treatment of patients with lower platelet counts (150-300× 109/L) was compared with that of patients with higher platelet counts (>300× 109/L) by the χ2 test. Overall and progression free survival Kaplan-Meier curves of the two groups were constructed and compared with the LogRank test. Results. A significant difference was present between the two groups in regards to pathologic response with patients with lower platelet counts being more likely to exhibit a good or complete response to neo-adjuvant treatment than patients with higher platelet counts (P = 0.015). There was also a significant difference between the CEA at presentation of patients that exhibited a good or complete response and those that had no response or a minimal to moderate response. Patients with a good or complete response were more likely to present with a CEA of less than 5 (P = 0.00066). There was no significant difference in overall and progression free survival between the two groups (LogRank tests p = 0.42 and p = 0.35, respectively). Conclusion. In this retrospective analysis of stage II and III rectal cancer patients, platelet counts at the time of diagnosis had prognostic value for neo-adjuvant treatment pathologic effect. Pre-treatment CEA also held prognostic value in regards to treatment effect. Citation Format: Ioannis Voutsadakis, Morgan Steele. Pre-treatment platelet counts as a prognostic factor in stage II and III rectal adenocarcinoma. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 484.

Abstract 484: Pre-treatment platelet counts as a prognostic factor in stage II and III rectal adenocarcinoma

View Online

Abstract

Details

Metrics